<?xml version="1.0" encoding="UTF-8"?>
<p>Favipiravir (FPV) a guanosine analog and an oral anti‐influenza drug that targets RNA‐dependent RNA polymerase (RdRP), which converts to active phosphoribosylated form in cells and acts as an RNA polymerase inhibitor. Also, favipiravir is a broad‐spectrum drug that blocks the replication of flavivirus, poliovirus, rhinovirus, filovirus, and arenaviruses. The effective dose of favipiravir used is Day 1: 1,600 mg twice daily, Days 2–5: 600 mg twice daily but its effective dose for treatment of COVID‐19, and 600 mg tid with 1,600 mg first loading dosage for no more than 14 days. However, favipiravir is contraindicated in pregnant women due to teratogenicity and embryotoxicity in animals and cannot be used in this group of patients (Delang, Abdelnabi, &amp; Neyts, 
 <xref rid="jcp29785-bib-0014" ref-type="ref">2018</xref>; Shiraki &amp; Daikoku, 
 <xref rid="jcp29785-bib-0050" ref-type="ref">2020</xref>).
</p>
